Trials / Approved For Marketing
Approved For MarketingNCT03723135
Expanded Access for CC-486
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-486 | Oral azacitidine administered as directed by treating physician. |
Timeline
- First posted
- 2018-10-29
- Last updated
- 2020-09-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03723135. Inclusion in this directory is not an endorsement.